- Barrons.com•last month
Maxim Group Adamis Pharmaceuticals announced that the Food and Drug Administration has accepted for review the New Drug Application for its epinephrine pre-filled syringe “PFS.” The FDA indicated that it considered the resubmission to be a complete response to the complete response letter. Recall that Adamis (ADMP) announced the resubmission of the NDA. The revised NDA addresses the issues in the letter received from the agency in June this year.
- GlobeNewswire•last monthAdamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, Jan. 19, 2017-- Adamis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration has accepted for review the Company’ s New Drug Application for its Epinephrine ...
- TheStreet.com•2 months ago
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
ADMP : Summary for Adamis Pharmaceuticals Corporat - Yahoo Finance
Adamis Pharmaceuticals Corporation (ADMP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.75 x 1000|
|Ask||3.75 x 100|
|Day's Range||3.25 - 3.35|
|52 Week Range||2.40 - 10.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|